Soru

Zorluk: OrtaMenstrual Cycle Abnormalities and Contraception

Seeking evaluation for increasingly erratic menstrual cycles, a 37-year-old nulligravid woman presents for a consultation. Over the last 14 months, her menses have occurred at unpredictable intervals of 45 to 70 days, accompanied by heavy flow lasting up to two weeks. During this time, she has also noticed new, coarse hair growth on her chin and chest. Her medical history is notable for asthma, obesity, and episodes of visual scotomata that precede severe, throbbing unilateral headaches. She currently takes no medications. She desires a reliable method of contraception as she anticipates becoming sexually active soon. Vital signs include a blood pressure of 138/88138/88 mmHg and a body mass index (BMI) of 3737 kg/m 2^2. A point-of-care urine pregnancy test is negative. Pelvic examination is limited by body habitus but reveals normal external genitalia and no palpable adnexal masses. Laboratory evaluation shows a normal serum thyroid-stimulating hormone (TSH) level and a normal serum prolactin concentration. Which of the following is the most appropriate next step in management?

  1. Endometrial biopsyCevap
  2. B
    Placement of a levonorgestrel-releasing intrauterine device
  3. C
    Prescription of combined oral contraceptives
  4. D
    Measurement of serum 17-hydroxyprogesterone
  5. E
    Measurement of serum free thyroxine

Cevap

The most appropriate next step is an endometrial biopsy to evaluate for endometrial hyperplasia or cancer.
The correct answer is endometrial biopsy. This patient presents with abnormal uterine bleeding (AUB) in the setting of chronic anovulation (suggested by hirsutism and irregular cycles, likely PCOS) and severe obesity. These conditions create a state of chronic, unopposed estrogen exposure, which causes continuous proliferation of the endometrial lining without the shedding effects of progesterone. This significantly increases her risk for endometrial hyperplasia and adenocarcinoma. According to ACOG guidelines, women under the age of 45 with AUB and risk factors for unopposed estrogen exposure (such as obesity or PCOS) require an endometrial biopsy as the initial diagnostic step to definitively rule out malignancy before any hormonal treatments or contraceptives are initiated.

Adım Adım Çözüm

1
Analyze the patient's presenting symptoms and risk factors.
The patient is a 37-year-old female with abnormal uterine bleeding (AUB), obesity (BMI 3737 kg/m 2^2), and signs of chronic anovulation (oligomenorrhea, hirsutism).
Identifying the clinical phenotype is necessary to determine the risk of underlying pathology, particularly the effects of unopposed estrogen on the endometrium.
2
Apply diagnostic guidelines for Abnormal Uterine Bleeding.
Current guidelines require an endometrial biopsy for women under age 45 with AUB who have additional risk factors for unopposed estrogen exposure, such as obesity and polycystic ovary syndrome (PCOS).
Chronic anovulation combined with peripheral conversion of androgens to estrone in adipose tissue results in continuous endometrial proliferation without progesterone withdrawal, significantly increasing the risk of endometrial hyperplasia and carcinoma.
3
Evaluate the patient's request for contraception against her medical history.
The patient has migraine with aura, which makes combined oral contraceptives an absolute contraindication (WHO MEC Category 4). While a levonorgestrel-releasing IUD is a safe future option, therapeutic interventions must wait.
Tissue diagnosis to rule out malignancy takes absolute precedence over initiating symptomatic treatment or contraception.

Anahtar Kavram

In premenopausal women under age 45 with abnormal uterine bleeding and risk factors for unopposed estrogen exposure (e.g., obesity, chronic anovulation), an endometrial biopsy is the mandatory first step to rule out endometrial hyperplasia and cancer before initiating medical therapy or contraception.
Bu soruyu puanla